Associate Professor Grant Comer, MD, MS, medical director of the KCRC, was instrumental in developing the space and the team. “Our vision was to expand Kellogg’s clinical research enterprise by streamlining and simplifying the whole process for both researchers and participating patients.”
The KCRC has more than realized that vision. Since opening its doors, clinical trial volume in ophthalmology has increased by more than 80 percent, including a number of highly complex gene therapy and stem cell therapy trials. “At the same time,” adds Dr. Comer, “we are an important partner for Michigan Medicine researchers in other specialties—from pediatrics to cancer—providing support for about 40 studies that require vision screening or monitoring for their participants.”
The KCRC conducts a variety of studies ranging from natural history studies to novel treatment trials. Studies span all sections within the Kellogg Eye Center, in hopes of better understanding eye conditions and discovering new ways to help as many of our patients as possible.